DNMT3B and seminoma: These data indicate that DNMT3B expression may be a potentially useful indicator for estimation of relapse risk in patients with stage I seminoma: patients whose tumours show such expression should be followed up as closely as, and for a longer period than, patients with non-seminomatous TGCTs.